X4 Pharmaceuticals (XFOR) Reports Q2 Loss, Beats Revenue Estimates
X4 Pharmaceuticals (XFOR) delivered earnings and revenue surprises of +31.58% and +340.30%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?